Companies
Claroty
publishes a documented case study of an Italian pharmaceutical multinational securing critical production plans and maintaining regulatory compliance without interrupting production, alongside dedicated guidance on securing OT in pharmaceutical and biotechnology.
- Country
- United States
Commercial
Coverage
| CN | EU | US | |
|---|---|---|---|
| digital-it | ✓ | ✓ | ✓ |
Regulatorsfdareach
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | 510.1 million Euros in 2024 | blog.claroty.com · claroty.com · it.claroty.com · social.claroty.com · casestudies.com |
| Capacity | 50 million/year, 115 million/year, 6 million/year, 75 million/year, 20 million patches/year, 35+ million towels/year, 3+ million lip sticks/year | fidiapharma.com |
| Certification | ISO 14001, ISO 9001, ISO 13485, GMP, ISO 22716 | fidiapharma.com |
| Regulatory approval | Authorized by AIFA | claroty.com · fidiapharma.com |
| Production site | Abano Terme (Padua), Noto (Syracuse), Paderno Dugnano (Milan), Monte Giberto (Fermo) | fidiapharma.com |
| Headcount | 1,700 employees worldwide | blog.claroty.com · claroty.com · it.claroty.com · social.claroty.com · casestudies.com · fidiapharma.ro |
| Revenue | 510.1 million Euros in 2024 | blog.claroty.com · claroty.com · it.claroty.com · social.claroty.com · fidiapharma.ro |
Independent sources: casestudies.com · fidiapharma.com · fidiapharma.ro
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Bio-cybersecurity | digital-it | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.